«Virometix - The future of vaccine design»
Presented by CTI Invest on 20.05.2010
Virometix develops first-in-class totally synthetic vaccines for the prevention and treatment of infectious diseases affecting millions of patients world-wide using its proprietary synthetic virus-like particle (SVLP) technology. SVLPs represent a new class of particle-based vaccine delivery vehicles that avoid the use of bacterial or viral components and do not incorporate poorly biocompatible materials like inorganic nanoparticles or synthetic polymers and offer advantages in terms or safety, stability, production and registration.
Coach: Dr. Marcos García Pedraza
| Founded |
2009 |
| Industry |
Biotech & Life Sciences
|
| Status |
looking for investor |